Clinical Trial Update: huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating huCART19-IL18-eDHFR cells for relapsed or refractory follicular lymphoma. The study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• huCART19-IL18-eDHFR cells

Snippet

Sponsor: University of Pennsylvania | Conditions: Relapsed or Refractory Follicular Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING